CCR8 Antibodies and Fusion Proteins for Cancer Treatment
Summary
The USPTO published patent application US20260098098A1 covering CCR8-binding antibodies and fusion proteins for cancer treatment. Inventors McGrath et al. filed Application No. 19182473 on April 17, 2025, with the application published on April 9, 2026. The patent covers therapeutic compositions and methods using CCR8-targeted biologics.
What changed
The USPTO published patent application US20260098098A1 for antibodies and fusion proteins that bind CCR8 for cancer treatment. The application covers novel therapeutic compositions and methods of treatment using CCR8-targeting biologics.
Pharmaceutical companies and biotech firms developing CCR8-targeted cancer immunotherapies should review the patent claims to assess potential licensing needs or design-around strategies. The IP filing date of April 17, 2025, establishes priority for the claimed compositions and methods.
What to do next
- Monitor for patent grant status
- Conduct Freedom to Operate analysis for CCR8-targeted cancer therapies
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF
Application US20260098098A1 Kind: A1 Apr 09, 2026
Inventors
Lara Lewis MCGRATH, Fabien DÉPIS, Changyun HU, Leonard G. PRESTA, Joshua Adam BUGGÉ
Abstract
Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
CPC Classifications
C07K 16/2866 A61P 35/00 A61K 2039/505 C07K 2317/24 C07K 2317/41 C07K 2317/565 C07K 2317/732 C07K 2317/734 C07K 2317/76 C07K 2317/92
Filing Date
2025-04-17
Application No.
19182473
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.